3 withdrawn, 2 not yet recruiting, 1 completed, 1 recruiting. 9 Phase 1, 8 Phase 2.
Follow Stevens-Johnson Syndrome: new trials by email Literature Review of Stevens-Johnson Syndrome trials Research Report on Stevens-Johnson Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| LYell SYndrome MEsenchymal Stromal Cells Treatment Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2024-04-15 | 2025-08-01 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis | Phase 1 / Phase 2 | Withdrawn | University of California, Davis | 2016-11-01 | 2019-08-09 | |
| Topical Infliximab in Autoimmune Eyes With Keratoprosthesis topical infliximab - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome | Phase 1 / Phase 2 | Withdrawn | James Chodosh, MD, MPH | 2014-11-01 | 2017-04-07 | |
| Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Riboflavin - Chemical Injuries, Unspecified Complication of Corneal Transplant | Phase 1 / Phase 2 | Completed | Joseph B. Ciolino, MD | 1 | 2012-03-01 | 2019-10-21 |
| Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Infliximab - Stevens-Johnson Syndrome, Corneal Blindness | Phase 1 / Phase 2 | Withdrawn | Massachusetts Eye and Ear Infirmary | 2010-12-01 | 2015-11-04 | |
| Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Palifermin - Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Terminated | Brett King | 1 | 2010-10-01 | 2016-11-30 |
Pemphigoid, Benign Mucous Membrane (3) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Lupus Erythematosus, Systemic (1) · Pemphigoid, Bullous (1) · Syndrome (1)
Chemically-Induced Disorders (9) · Dermatitis (9) · Drug Eruptions (9) · Drug Hypersensitivity (9) · Drug-Related Side Effects and Adverse Reactions (9) · Erythema (9) · Erythema Multiforme (9) · Hypersensitivity (9) · Hypersensitivity, Delayed (9) · Immune System Diseases (9) · Mouth Diseases (9) · Skin Diseases (9) · Skin Diseases, Vesiculobullous (9) · Skin and Connective Tissue Diseases (9) · Stomatitis (9)
Infliximab (2) · Adalimumab (1) · Clobetasol (1) · Fibroblast Growth Factor 7 (1) · Ointments (1) · Riboflavin (1) · Solutions (1) · daratumumab (1)
Massachusetts Eye and Ear Infirmary (2) · Assistance Publique - Hôpitaux de Paris (1) · Brett King (1) · Hospices Civils de Lyon (1) · Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1) · James Chodosh, MD, MPH (1) · Joseph B. Ciolino, MD (1) · University of California, Davis (1)
United States (6) · France (2) · Canada (1) · Spain (1)
James Chodosh, MD, MPH (2) · Claes H Dohlman, MD, PhD (1) · Emanual Maverakis, MD (1) · Joseph Ciolino, MD (1) · Mona Harissi-Dagher, MD (1) · Saskia Oro, PhD (1) · Thomas Dohlman, MD (1)